Commitment in 31 million beats per year
Since its foundation in 2013, OMEICOS has assembled an exceptional team of interdisciplinary and highly motivated individuals that form the backbone of our company.
Our team has made unprecedented scientific advancements, thanks to its dedication and tireless efforts. With support from our investors and collaboration partners, the OMEICOS team is forging ahead to provide breakthrough treatment options for patients. Our primary focus is in cardiovascular disease with potential future applications branching out into eye diseases and other areas with significant medical need.
“We are extremely proud of our team and our corporate culture that relies on the sovereignty of exciting state-of-the-art science and a multi-disciplinary team acting fast through flat hierarchies, being united in the desire to make a difference in the lives of patients. I’d like to thank all current and former colleagues for their contribution which has brought us to where we are today; being a leading biopharmaceutical company with a pipeline headed by a Phase II product exploiting a fundamentally new approach in human biology.”
DR. ROBERT FISCHER, CO-FOUNDER,
CEO AND CSO OF OMEICOS THERAPEUTICS